Detralex tab. p / o captivity. 500 mg # 30
Package quantity, pcs:
thirty
60
Dosage:
100mg + 900mg
500mg
Release form:
Oral suspension
Tablet
Category
Diseases of the veins
Scope of the drug
Heart, vessels, blood
Release form
Tablet
Manufacturer country
Russia
Package quantity, pcs
thirty
Latin name
Detralex
Release form
Pills
Packaging
30 pcs.
pharmachologic effect
Detralex has venotonic and angioprotective properties.
The drug reduces the distensibility of veins and venous stasis, reduces capillary permeability and increases their resistance.
The results of clinical studies confirm the pharmacological activity of the drug in relation to the parameters of venous hemodynamics.
The statistically significant dose-dependent effect of Detralex was demonstrated for the following venous plethysmographic parameters: venous capacity, venous extensibility, and venous emptying time.
The optimal dose / effect ratio is observed when taking 2 tablets.
Detralex increases venous tone: with the help of venous occlusive plethysmography, a decrease in the time of venous emptying has been shown.
In patients with signs of severe microcirculation disorders, there is (statistically significant), compared with placebo, an increase in capillary resistance, assessed by angiostereometry, after therapy with Detralex.
The therapeutic efficacy of Detralex has been proven in the treatment of chronic diseases of the veins of the lower extremities, as well as in the treatment of hemorrhoids.
Pharmacokinetics
The main excretion of the drug occurs in the feces.
With urine, on average, about 14% of the taken amount of the drug is excreted.
T1 / 2 is 11 hours.
The drug undergoes active metabolism, as evidenced by the presence of phenolic acids in the urine.
Indications
Symptomatic therapy of venous lymphatic insufficiency, feeling of heaviness in the legs, pain, morning fatigue" of the legs, convulsions, trophic disorders, symptomatic therapy of exacerbation of hemorrhoids.
Contraindications
Hypersensitivity to drug components.
Application during pregnancy and lactation
Pregnancy
Animal experiments have not revealed teratogenic effects.
Until now, there have been no reports of any side effects when using the drug by pregnant women.
Lactation
Due to the lack of data on the excretion of the drug into breast milk, lactating women are not recommended to take the drug.
special instructions
In case of exacerbation of hemorrhoids, the appointment of this drug does not replace the specific treatment of other anal disorders.
The duration of treatment should not exceed the recommended period.
In the event that the symptoms do not disappear after a short therapy, a proctological examination should be performed and the ongoing therapy should be reviewed.
In the presence of venous circulation disorders, the maximum effect of treatment is provided by a combination with a healthy, well-balanced lifestyle, in which it is desirable to avoid prolonged exposure to the sun, reduce body weight, go for walks and in some cases wear special socks that improve blood circulation.
Influence on the ability to drive vehicles and use mechanisms
The drug does not affect the ability to drive vehicles and perform work that requires a high speed of psychomotor reactions.
Structure
1 tablet contains:
Active ingredients: purified micronized flavonoid fraction 500 mg (including diosmin (90%) 450 mg, flavonoids, expressed as hesperidin (10%) 50 mg)
Excipients: gelatin, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, talc, glycerol, macrogol 6000, hydroxypropyl methylcellulose, iron oxide yellow (E172), iron oxide red (E172), titanium dioxide (E171), sodium lauryl sulfate.
Method of administration and dosage
The drug is taken orally.
The recommended dose is 2 tablets per day, 1 tablet in the middle of the day and 1 tablet in the evening with meals.
In the period of exacerbation of hemorrhoids - 6 tablets per day for 4 days, then 4 tablets per day for the next 3 days.
Side effects
From side
Name ENG
DETRALEX
Clinical and pharmacological group
Venotonic and venoprotective drug
ATX code
Diosmin in combination with other drugs
Dosage
500mg
Structure
1 tablet contains: Active ingredients: purified micronized flavonoid fraction 500 mg (including diosmin (90%) 450 mg, flavonoids, expressed as hesperidin (10%) 50 mg)
...
Excipients: gelatin, magnesium stearate, microcrystalline cellulose, sodium starch glycolate, talc, glycerol, macrogol 6000, hydroxypropyl methylcellulose, iron oxide yellow (E172), iron oxide red (E172), titanium dioxide (E171), sodium lauryl sulfate.
Indications
Symptomatic therapy of venous lymphatic insufficiency, feeling of heaviness in the legs, pain, "morning fatigue" of the legs, convulsions, trophic disorders, symptomatic therapy of exacerbation of hemorrhoids.
Storage conditions and periods
At a temperature not higher than 30 degrees.
Expiration date: 4 years
INN / Active ingredient
Hesperidin, Diosmin
Contraindications
Hypersensitivity to drug components.
Specifications
Category
Diseases of the veins
Scope of the drug
Heart, vessels, blood
Release form
Tablet
Manufacturer country
Russia
Package quantity, pcs
thirty
Way of introduction
Through the mouth
Vacation conditions
Without recipe
Brand name
Servier
The amount of the dosage form in the primary package
15 pcs.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Venotonic and venoprotective agent
Anatomical and therapeutic characteristics
C05CA53 Diosmin, in combination with other drugs
Dosage form
Film-coated tablets
Expiration date in days
1460
Dosage (volume) of the substance in the preparation
500 mg + 50 mg
Package weight, g
35
Mode of application
:
The drug is taken orally.
< br> < br> The recommended dose is 2 tablets per day, 1 tablet - in the middle of the day and 1 tablet - in the evening during meals.
< br> < br> During the period of exacerbation of hemorrhoids - 6 tablets per day for 4 days, then 4 tablets per day for the next 3 days.
Information on technical characteristics, delivery set, country of manufacture "